No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FDA Accepts Hikma/Richter’s Biosimilar Denosumab Application
On 12 December 2024, Gedeon Richter and Hikma Pharmaceuticals announced that FDA has accepted for review Hikma’s BLA for RGB-14 (denosumab), biosimilar to Amgen’s Prolia® and Xgeva®.